Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CBLL
CBLL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CBLL News
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
Jan 16 2026
Globenewswire
CeriBell (CBLL) Receives FDA Breakthrough Device Designation for Stroke Detection Monitor
Jan 05 2026
NASDAQ.COM
CeriBell CEO Jane Chao to Present at 2026 J.P. Morgan Healthcare Conference
Dec 30 2025
Globenewswire
Ventripoint Partners with Nisg̱a'a to Advance Cardiac Imaging in Remote Communities
Dec 12 2025
PRnewswire
Ventripoint Partners with Nisg̱a'a for Advanced Cardiac Imaging
Dec 12 2025
Newsfilter
CeriBell Stock Jumps 5.4% Following FDA Approval of Innovative Delirium EEG Device
Dec 09 2025
NASDAQ.COM
Major Stocks Including Academy Sports and Outdoors, Tronox, and STAAR Surgical See Gains on Tuesday
Dec 09 2025
Benzinga
Aleen Inc. Launches Personal Account System, Seeks $20M-$30M Investment
Dec 09 2025
Newsfilter
CeriBell Receives FDA Clearance for First Continuous Delirium Monitoring Device
Dec 09 2025
Newsfilter
CeriBell Receives FDA Clearance for Next-Gen Neonatal Seizure Detection Technology
Nov 24 2025
Newsfilter
CeriBell (CBLL) Third Quarter 2025 Earnings Call Summary
Nov 09 2025
NASDAQ.COM
JP Morgan Keeps Overweight Rating on CeriBell, Adjusts Price Target to $17
Nov 05 2025
Benzinga
TD Cowen Keeps Buy Rating on CeriBell, Reduces Price Target to $20
Nov 05 2025
Benzinga
Raymond James Begins Coverage of CeriBell with a Strong Buy Rating and Sets Price Target at $19
Oct 21 2025
Benzinga
CeriBell (CBLL) Q2 Revenue Jumps 38%
Aug 06 2025
NASDAQ.COM
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Jul 07 2025
Newsfilter
Show More News
